Kala Reports Positive Results for Phase III Trial of KPI-121 for Post-Cataract Surgery Pain, Inflammation

May 12, 2017: By Jon Swedien

KalaA confirmatory Phase III trial for Kala Pharmaceuticals’ product candidate for post-cataract surgery pain and inflammation produced positive topline results, the Waltham, Massachusetts, company announced May 1.

KPI-121 is a novel nanoparticle formulation of loteprednol etabonate using Kala’s mucus-penetrating particle technology to enhance penetration into tissues of the eye.

The company said it intends to submit a new drug application to the US FDA in late 2017.

In the Phase III multicenter, randomized, double-masked trial of 520 patients, KPI-121 1% was dosed twice daily for two weeks and achieved statistical significance versus placebo for both primary efficacy endpoints and all secondary endpoints, Kala said.

The primary efficacy endpoints were the proportion of patients with complete resolution of anterior chamber cells—a marker of ocular inflammation—in the study eye at day eight, and the proportion of subjects with grade zero pain in the study eye at day eight, Kala said.

Secondary endpoints were complete resolution of anterior chamber flare at day four, complete resolution of pain at day four, and mean change in anterior chamber cells at day four. Each case maintained through day 15 with no need for rescue medication, Kala said.

The positive results followed Kala’s first Phase III trial for KPI-121 1% for post-cataract surgery pain and inflammation that concluded in 2015. In 380 patients, the treatment achieved complete resolution of ocular pain by the eighth day of treatment.

Kala also is studying KPI-121’s effectiveness as a proposed dry eye treatment in a pair of Phase III trials, expected to be completed by the end of 2017.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Ophthalmic Devices Panel to hold Meeting Oct. 27

Novartis’ RTH258 Successful in Two Phase III Studies for nAMD

Ocugen Closes $7.5 Million Series B Round

Genentech Uses Vital Art and Science Vision-Testing App in Phase II Study of Sustained Delivery of Lucentis

US Supreme Court Ruling Shortens Time to Market for Biosimilars

Ellex Acquires Royalty Commitment for iTrack Device for $2.15 Million

Johnson & Johnson Vision Names Jonathan Talamo, MD, Chief Medical Officer

Teva Launches Generic Versions of Pataday in US

David Karcher Stepping Down as Executive Director, CEO of ASCRS

EyeGate Raises $10 Million in Public Offering

Aerie Raises $125 Million through Upsized Public Offering, ATM Program

pSivida’s Durasert for Posterior Segment Uveitis Successful in Second Phase III Study

Mynosys Zepto Receives US FDA 510(k) Clearance

Ozurdex, Humira Gain NICE Backing for Non-infectious Posterior Uveitis

Roger Steinert, Pioneer in Ophthalmology, Dies at 66

Carl Zeiss Meditec to Build New Innovation Center in Northern California

Gottlieb Says FDA to Publish List of Drugs Without Generic Competition

REGENXBIO Announces Phase I Clinical Trial for RGX-314 Gene Therapy for Wet AMD

Belkin Laser Closes Nearly $5 Million Financing Round

Valeant in Talks to Sell Surgical Business to Carl Zeiss Meditec

Coming soon

2017 Cataract Surgical Equipment: A Global Market Analysis for 2016 to 2022